THER has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
THER has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Theralink Technologies's Enterprise Value is $28.04 Mil. Theralink Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $6.12 Mil. Therefore, Theralink Technologies's EV-to-EBIT ratio for today is 4.58.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Theralink Technologies's Enterprise Value is $28.04 Mil. Theralink Technologies's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $6.32 Mil. Therefore, Theralink Technologies's EV-to-EBITDA ratio for today is 4.44.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Theralink Technologies's Enterprise Value is $28.04 Mil. Theralink Technologies's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.64 Mil. Therefore, Theralink Technologies's EV-to-Revenue ratio for today is 44.15.
The historical data trend for Theralink Technologies's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralink Technologies Annual Data | |||||||||||||||||||||
Trend | Feb14 | Feb15 | Dec16 | Dec17 | Dec18 | Dec19 | Sep20 | Sep21 | Sep22 | Sep23 | |||||||||||
Enterprise Value | Get a 7-Day Free Trial | 3.54 | 1,614.71 | 259.36 | 28.51 | 24.30 |
Theralink Technologies Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Enterprise Value | Get a 7-Day Free Trial | 22.83 | 21.43 | 27.86 | 24.30 | 32.96 |
For the Biotechnology subindustry, Theralink Technologies's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Theralink Technologies's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Theralink Technologies's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Theralink Technologies's Enterprise Value for the fiscal year that ended in Sep. 2023 is calculated as
Enterprise Value (A: Sep. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 5.53635 | + | 0 | + | 1.131 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 18.631 | + | 0 | - | 0.998 |
= | 24.30 |
Theralink Technologies's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as
Enterprise Value (Q: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 9.22725 | + | 0 | + | 1.117 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 22.638 | + | 0 | - | 0.024 |
= | 32.96 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralink Technologies (OTCPK:THER) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Theralink Technologies's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 28.038 | / | 6.117 | |
= | 4.58 |
Theralink Technologies's current Enterprise Value is $28.04 Mil.
Theralink Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.12 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Theralink Technologies's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 28.038 | / | 6.32 | |
= | 4.44 |
Theralink Technologies's current Enterprise Value is $28.04 Mil.
Theralink Technologies's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.32 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Theralink Technologies's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 28.038 | / | 0.635 | |
= | 44.15 |
Theralink Technologies's current Enterprise Value is $28.04 Mil.
Theralink Technologies's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Theralink Technologies's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Danica Holley | director | 7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814 |
Matthew Wilson Schwartz | director | 15000 W. 6TH AVENUE, SUITE 400, GOLDEN CO 80401 |
Chilcott, Iii Thomas E. | officer: Chief Financial Officer | 373 INVERNESS PARKWAY, ENGLEWOOD CO 80122 |
Jeffrey Busch | director | 7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814 |
Yvonne Fors | director | 1201 MONSTER RD SW STE 350, RENTON WA 98057 |
Michael I Ruxin | director, officer: Chief Executive Officer | HAEMONETICS CORPORATION INCORPORATED, 400 WOOD ROAD, BRAINTREE MA 02184 |
Avant Diagnostics, Inc | 10 percent owner | 1050 30TH STREET NW, SUITE 107, WASHINGTON DC 20007 |
Brian Gill Barnett | officer: Chief Executive Officer | 230 N SPRINGER, LOS ALTOS CA 94024 |
Robert Neal Holcomb | director | PO BOX 535, ROLLING FORK MS 39159 |
Volnie Carlos Fernando Alaman | 10 percent owner, officer: Chief Operating Officer-Vitel | MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000 |
Odabachian Manuel Cosme | director, 10 percent owner, officer: Global Operations GM-Vitel | MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000 |
Daniel S. Hoverman | director | C/O ONCBIOMUNE PHARMACEUTICALS INC.,, 11441 INDUSTRIPLEX BLVD, SUITE 190, BATON ROUGE LA 70809 |
Rice Charles L Jr | director | C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113 |
Andrew Albert Kucharchuk | director, officer: CFO & President | 549 MILGATE PLACE, BATON ROUGE LA 70810 |
Jonathan Frederick Head | director, officer: Chief Executive Officer | 6144 HAGERSTOWN DRIVE, BATON ROUGE LA 70817 |
From GuruFocus
By PRNewswire PRNewswire • 09-29-2020
By PRNewswire PRNewswire • 07-15-2022
By PRNewswire PRNewswire • 01-27-2021
By ACCESSWIRE ACCESSWIRE • 08-25-2020
By PRNewswire PRNewswire • 06-15-2022
By PRNewswire PRNewswire • 03-28-2022
By PRNewswire PRNewswire • 11-14-2022
By PRNewswire PRNewswire • 06-25-2022
By PRNewswire PRNewswire • 11-07-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.